Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline
Retrieved on:
Thursday, September 9, 2021
Through our collaboration with PeptiDream, we have evaluated several optimized macrocyclic peptide GHRAs, and we have selected AZP-3813 as our lead product candidate.
Key Points:
- Through our collaboration with PeptiDream, we have evaluated several optimized macrocyclic peptide GHRAs, and we have selected AZP-3813 as our lead product candidate.
- We anticipate developing AZP-3813 as a potential next-generation GHRA therapeutic to provide greater efficacy to a broader range of patients with acromegaly.
- Patrick C. Reid, Ph.D., president and chief executive officer of PeptiDream, added, We are very pleased to have identified an optimized drug candidate for further development in acromegaly through our research collaboration with Amolyt Pharma.
- With their peptide development capabilities, we believe Amolyt Pharma is well-suited to develop this therapeutic and to bring a much-needed new treatment option to acromegaly patients.